DDMED 48 Clinical Guide to Medical and Psychiatric Management of Sleep Disorders in the Adult Patient with Mental Retardation and

Similar documents
Practical Management of the Delirious Patient with Mental Retardation by the Nurse Anesthetist

Insomnia. Learning Objectives. Disclosure 6/7/11. Research funding: NIH, Respironics, Embla Consulting: Elsevier

Benzodiazepines: Comparative Effectiveness and Strategies for Discontinuation. Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project

Individual Planning: A Treatment Plan Overview for Individuals Sleep Disorder Problems.

AGING CHANGES IN SLEEP

SEDATIVE-HYPNOTIC AGENTS

How to Manage Insomnia with and without medications

SLEEP STUDY. Nighttime. 1. How many hours of sleep are you now getting in a typical night?

Anxiolytic and Hypnotic drugs

Using Benzodiazepines in Primary Care

Anxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Many people with physical

Guideline for Adult Insomnia

OBJECTIVES. The psychiatric, medical, and neurologic causes of sleep problems. Office-based and objective methods of evaluating sleep

TEST BANK FOR GERONTOLOGICAL NURSING 3RD EDITION BY TABLOSKI Chapter 08

Objectives. Types of Sleep Problems in Developmental Disorders

Insomnia % of adults suffer from chronic and severe insomnia (Complaints of insomnia with daytime consequences)

Sleep and Parkinson's Disease

11/1/2010. Psychology 472 Pharmacology of Psychoactive Drugs. Listen to the audio lecture while viewing these slides

Pharmacological Help for a Good Night s s Sleep. Thomas Owens, MD

WHY CAN T I SLEEP? Deepti Chandran, MD

Sleep and Traumatic Brain Injury (TBI)

Available Strengths Limits. 200 mg tablets PA. 50 mg, 150 mg, 200 mg, 250 mg tablets. 500 mg/ml solution PA

WHEN AND HOW TO USE BENZODIAZEPINES IN TREATING ANXIETY: AM I WITHHOLDING TREATMENT IF I DON'T USE BENZODIAZEPINES?

Dr Alex Bartle. Sleep Well Clinic

MMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA

Earl J. Soileau, MD, FSAHM Asst Professor, Family Medicine LSU HSC Medical School New Orleans at Lake Charles

Pediatric Sleep Questionnaire

RETT SYNDROME AND SLEEP

Sweet Dreams: The Relationship between Sleep Health and Your Weight

Facts about Sleep. Circadian rhythms are important in determining human sleep patterns/ sleep-waking cycle

Insomnia treatment. Sleep hygiene education sleep hygiene teaches good sleeping habits. This includes:

Addressing the Multiple Causes and Lifestyle Impacts of Insomnia: A Guide for Patient Counseling

You May Be at Risk. You are taking one of the following sedative-hypnotic medications: Diazepam (Valium ) Estazolam. Flurazepam.

You May Be at Risk. You are taking one of the following sedative-hypnotic medications:

Objectives. Sleep Problems in the Child with Physical Disabilities AACPDM September 14, Types of Sleep Problems

Insomnia. St. Joseph s Annual Family Practice Refresher March 1, Robert J. Ostrander, M.D

General Questionnaire

You May Be at Risk. You are currently taking a sedative-hypnotic drug. Please Bring This Information With You To Your Next Medical Appointment

Sleep History Questionnaire

Sleep Hygiene. William M. DeMayo, M.D. John P. Murtha Neuroscience and Pain Institute Conemaugh Health System Johnstown, PA

CPT David Shaha, MC US Army

Zopiclone Orion. Date: , Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Temazepam 30 mg sleeping pills

CHOOSING WISELY TO IMPROVE CARE FOR GERIATRIC PATIENTS

HOW TO DEAL WITH SLEEP PROBLEMS

Sleep Center. Have you had a previous sleep study? Yes No If so, when and where? Name of facility Address

Dr Laith M Abbas Al-Huseini M.B.Ch.B, M.Sc., M.Res., Ph.D.

Beyond Sleep Hygiene: Behavioral Approaches to Insomnia

노인병원에서 Light Therapy 의 활용 박 기 형 진주삼성병원 송도병원 신경과

Sleep Questionnaire. If yes, what? If yes, how would you describe it? Please explain? If yes, what times are these?

The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State

DRUGS THAT ACT IN THE CNS

Anxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM

Tranquilizers & Sedative-Hypnotics

Sleeping with PD. Jean Tsai, MD PhD September 27, 2014

ADULT PRIMARY INSOMNIA

Patient Information. Name: Date of Birth: Address: Number & Street City State Zip Code. Home Number: ( ) Cell Number: ( )

Managing Insomnia Disorder A Review of the Research for Adults

Benzodiazepines and Hypnotics

INDEX. Group psychotherapy, described, 97 Group stimulus control, 29-47; see also Stimulus control (group setting)

Modern Management of Sleep Disorders. If Only I Could Sleep Like I Did Before

Article printed from

SLEEP-WAKE DISORDERS: INSOMNIA. Prof. Paz Gía-Portilla

Can benadryl cause urinary retention

SLEEP QUESTIONNAIRE. Please briefly describe your sleep or sleep problem:

Modern Management of Sleep Disorders

Sedatives and Hypnotics. Ahmad Al-Tarifi. Zahra Khalil. Pharmacology. 1 P a g e

Sleep History Questionnaire

PRACTICAL MANAGEMENT OF INSOMNIA IN THE OFFICE

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017

Sleep and Falls. Katie L. Stone, Ph.D. October 4-6, 2015

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan

Sleep Disorders: Assessment and Therapeutic Options

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan

Sleep Disorders. Guidance for Primary Care. National Advisory Group for Respiratory Managed Clinical Networks

Insomnia treatment in primary care

Patient Scheduled Letter Thunderbird Internal Medicine Sleep Center 5620 W. Thunderbird Rd., Suite C-1 Glendale, AZ (602)

Sleep Complaints and Disorders in Epileptic Patients 순천향의대천안병원순천향의대천안병원신경과양광익

Question #1. Disclosures. CAPA 2015 Annual Conference. All of the following occur as we get older EXCEPT: Evaluating Patients with Insomnia

Benzodiazepines: risks, benefits or dependence

SLEEP & MEDICAL HISTORY QUESTIONNAIRE

Chronic Insomnia: DSM - V. Insomnia DSM - V. Patient Symptoms. Insomnia: Assessment and Overview of Management. Insomnia Management in the Digital Age

Module 22: Fact or Falsehood?

SLEEP EVALUATION QUESTIONNAIRE

Reduction in the Use of Night Sedation to Reduce the Risk of Falls

Index SLEEP MEDICINE CLINICS. Note: Page numbers of article titles are in boldface type.

INSOMNIA IN THE GERIATRIC POPULATION. Shannon Bush, MS4

Psychopharmacology of Sleep Disorders

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

Sleep and Epilepsy. Nancy Foldvary-Schaefer, DO, MS

Sleep Center New Patient Questionnaire

Insomnia: Updates in Medical Management. Michael Newnam M.D.

Clonazepam temazepam clonazepam temazepam compared temazepam clonazepam klonopin temazepam Clonazepam vs Temazepam Clonazepam Temazepam Temazepam

Insomnia. Dr Terri Henderson MBChB FCPsych

Sedative/Hypnotic Agents. Sedative/Hypnotic Agents. Central Nervous System Depressants. Sedative/Hypnotic Agents(cont d) Sleep

Introduction. v Insomnia is very prevalent in acute (30-50%) and chronic forms (10-15%). v Insomnia is often ignored as a symptom of other disorders.

WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS

Insomnia Restoring Restful Sleep

Sleep - Definition. Slide 1 Sleep & Developmental Disabilities: Lessons for All Children. Slide 2 Importance of Sleep. Slide 3. Lawrence W.

Transcription:

Clinical Guide to Medical and Psychiatric Management of Sleep Disorders in the dult Patient with Mental Retardation and Developmental Disabilities (MR/DD) 1. Overview The reported rates of sleep disorders in the population with MR/DD range from 13% to 86% (1). These patients may exhibit the full range of sleep disorders identified in other groups. The rates of sleep disorder may vary according to severity of intellectual disability, type of neurological disability, associated medical problems, and intensity of nocturnal stimulation. The rate of sleep problems may vary according to location of residence. Community-dwelling individuals in residential living demonstrate a range of sleep disorders, including problems with sleep induction (26.8%), nighttime awakening (55.6%), parasomnia (14%), and sleep-related breathing problems (15%) (2). Severe locomoter disability, blindness and active epilepsy will increase the likelihood of daytime sleepiness (3). The diagnosis of sleep disorder requires a comprehensive, medical, psychiatric, behavioral, and environmental evaluation to exclude potential causes for the sleep disorder (4). Sedative-hypnotics should only be prescribed as a last option, as these medications have numerous side effects in the person with MR/DD (5). Brain damage that produces MR may also disrupt circadian rhythms. Some moderate to severely retarded individuals may sleep 4 to 6 hours at night and this shortened cycle may be unavoidable. 2. Differential Diagnosis of Excessive Daytime Sleepiness Excessive, daytime sleepiness can be produced by many clinical conditions (4). Staff should observe the number and duration of sleep episodes during daytime. The differential diagnosis depends upon whether the daytime drowsiness is chronic or acute. cute, daytime sleepiness can be caused by many problems including excessive sedation, delirium, depression, boredom, or unrecognized medical problems such as endocrine dysfunction, seizures, or heart failure (6), (7). The acute onset of daytime sleepiness should warrant a complete physical and psychiatric evaluation. Obese patients may be at risk for Pickwickian syndrome and certain neurological disorders may produce sleep attacks (4). Some patients will sleep during the daytime because they are bored or remain awake at night due to excessive environmental stimulation, such as a roommate who snores, screams or turns on the radio (1). These patients require structured daytime activities and a behavioral assessment to manage this behavioral complication. Nocturnal environmental disruptions should be corrected, such as loud noises, yelling, music, etc. Depression can cause isolated daytime sleepiness in the absence of other depressive symptoms. Chronic, daytime sleepiness may require evaluation in a sleep study center by a sleep specialist to exclude other potential causes for sleep disturbance. Stimulants can be used to enhance alertness after a comprehensive evaluation to exclude other causes such as sleep apnea. These 1

medications should be a last option as these medications have numerous side effects including agitation, addiction, mania, and worsening of psychosis (8). 3. Differential Diagnosis of Insomnia (Table 1) Insomnia is a common problem; especially for institutionalized persons. The differential diagnosis of insomnia includes medical, psychiatric, and behavioral problems. The clinician must determine whether the insomnia is acute, chronic, or situational. brupt onset insomnia implies some new medical, psychiatric, or behavioral problem. Medications can produce insomnia, especially bronchial-dilators, e.g., theophyline, lbuterol, antidepressants, and caffeinated beverages (7). Noisy, chaotic, sleeping environments, can produce insomnia in all patients, e.g., screaming roommate, noisy day areas, etc. Psychiatric problems produce insomnia, including depression, mania, anxiety, delirium, and psychosis. Post-traumatic stress disorder can produce a range of sleep problems. Specific types of medical problems can awaken a patient at night including pain, respiratory difficulties, and urinary urgency (6), (7). Table 1. Differential Diagnosis of Sleep Disorders. Excessive Daytime Sleepiness Environmental Disruption of Sleep Delirium Depression Primary Sleep Disorder Medical Problems Sleep pnea B. Insomnia Poor Sleep Hygiene Environmental Chaos Medical Problems Delirium Unmet Needs Restless Leg Syndrome 4. ssessment of Sleep Disorders The assessment should include evaluation to exclude new health problems or medication changes. sleep scan can be performed on patients with a possible diagnosis of sleep disturbance. proper sleep survey is essential and staff should not inadvertently awaken patients while they check them for their sleep status. Epileptic patients may sometimes awaken following a nighttime seizure and seizure disorder is a risk factor for sleep disturbance (3). Some patients may awaken because of hunger, thirst, or discomfort in the bed, e.g., wet from incontinence of urine or feces. Some medical problems will awaken patients with MR/DD including asthma, pain, muscle spasm or congestive heart failure (3). The patient with MR/DD is less likely to engage in physical exercise on a regular basis than the general population and over 3/4 will not achieve minimum activity (9). Low levels of physical exercise and high levels of sedentary behavior increase the likelihood of daytime napping and nighttime insomnia. Physical and mental stimulation during the daytime may lessen the likelihood of daytime napping and nighttime sleep disruption. Many persons with intellectual disability are obese. Obesity and neurological disorders may increase the likelihood of sleep apnea. Staff can monitor patient s sleep at night to document excessive snoring or episodes with prolonged cessation of breathing. Over 1/4 of obese patients with MR/DD can reduce weight with behavioral interventions (10). variety of medications can induce restless leg syndrome that produces nocturnal restlessness. Patients with symptoms of sleep apnea can be evaluated at a sleep study center and continuous positive airway pressure (CPP) can be used if the patient is sufficiently compliant to keep equipment on the face (3). 2

Once there is reasonable certainty that there are no medical explanations for excessive daytime sleepiness, insomnia, or nocturnal restlessness, an assessment of psychiatric symptoms should be conducted. Individuals with intellectual disabilities are more likely to have behavioral manifestations of psychiatric symptoms when they occur and are less likely to be able to verbalize in a sophisticated way about what they are experiencing. Some assessment tools designed for aiding the identification of psychiatric symptoms in individuals with intellectual disabilities include the DSH-II (Diagnostic ssessment for the Severely Handicapped II), the DD (ssessment of Dual Diagnosis), and the REISS Screen. These instruments have taken symptoms for the various diagnostic categories in the DSM and translated them into descriptions of behaviors that have been associated with particular diagnostic categories. This kind of assessment can also help sort out which behaviors are manifestations of a psychiatric disorder and which behaviors are a result of learning. Functional behavioral assessments need to be conducted for the latter when identified. 5. Therapy for Sleep Disorders (Table 2) Therapy begins with correction of any medical, environmental or personal care problem that may disrupt sleep (1). The expert consensus panel discourages the use of medications to induce sleep in persons with MR/DD (7), (8). Pharmacological therapy for insomnia is usually the last treatment option. Specific sleep disorders, e.g., sleep apnea, require appropriate intervention, e.g., continuous positive airway pressure (CPP) therapy. cute insomnia produced by psychological traumas such as abuse or changes of living environment are appropriate indications for short-term use of sedative-hypnotics while behavioral or psychological interventions reduce stress and anxiety. Zolpidem 5mg qhs or Desyrel 25-50mg hs can be used to assist with sleep for one or two weeks. The consensus guidelines for treatment of insomnia encourage minimal use of benzodiazepines. Benzodiazepines and barbiturates should be avoided because these medications can produce confusion and rarely correct chronic insomnia (11), (12). Chloral hydrate and meprobamate are not recommended for use in persons with MR/DD. Long, half-life benzodiazepines such as Klonipin, Valium, Librium or Dalmane should not be used for sleep purposes. Over-the-counter preparations, such as diphenhydramine, hydroxyzine, and alcohol produce no significant hypnotic effect but rather sedate and confuse the person with MR/DD. The therapeutic efficacy of nightly benzodiazepine therapy for insomnia is usually diminished after 4-6 weeks producing the need for escalating doses of medication to maintain sleep. Discontinuation of the benzodiazepine Table 2 Efficacy of Sedative Hypnotics for du with MR/DD cute, Short-term Chronic Long-ter Temazepam H Zolpidem H C Trazedone H C Benadryl Vistaril Seconal Klonopin Meprobamate Chloral Hydrate 3

can produce rebound insomnia. In general, long-term benzodiazepine therapy for sleep produces more side effects than benefits, including increased risk for falls, GERD, and other accidents (5). The long-term management of sleep disorders focuses on behavioral interventions to assist with sleep and medical or psychiatric interventions to reduce disorders that worsen insomnia. Pharmacological interventions are best limited to Desyrel, zolpidem and eszopiclone (See Table 2 and 3). Physicians should avoid medications that produce daytime sleepiness and minimize medications that produce insomnia. Sedating medications, such as antipsychotics, should be prescribed at bedtime to facilitate sedation but these medications are not indicated for the treatment of sleep disorders (11), (12), (13). Table 3 Commonly Used Dosing Ranges for Benzodiazepine nxiolytic or Sedative/Hypnotic Medications for the dult Population with MR/DD DRUG Diazepam (VLIUM) Clonazepam (KLONOPIN) Chlordiazepoxide (LIBRIUM) lprazolam (XNX) Temazepam (RESTORIL) Lorazepam (TIVN) Oxazepam (SERX) Zolpidem (MBIEN) Eszopiclone (LUNEST) HELTHY/DULT DILY DOSE RNGE FRIL/ELDELRY DILY DOSE RNGE COMMENTS See PDR for Complete Details INDICTION FOR SLEEP Long cting (t1/2>24hrs) ---- ---- Very Fast Onset of ction ---- ---- No ctive Metabolites ---- ---- Useful Treating lcohol Withdrawal Intermediate cting (t1/2 = 12-24hrs) ---- ---- Fast Onset of ction 7.5-30mg 7.5 15mg No ctive Metabolites C 0.5-1mg 0.25 0.5mg No ctive Metabolites C 7.5 30mg 7.5 15mg No ctive Metabolites C Short cting (t1/2<12hrs) 5-10mg 5mg Only Indicated for cute R Insomnia 1 3mg 1 2mg Indication for Chronic R Insomnia ll benzodiazepine medications may be addictive and produce delirium, falls, or excessive sedation. These medications are not recommended for children. void Use C-can be used with caution R-can be used for insomnia Chronic sedative-hypnotic usage should be avoided for the person with MR/DD until a complete medical and psychiatric evaluation is completed and the behavioral analyst has excluded all potential behavioral explanations for insomnia. ntipsychotic medications are never indicated for sleep disturbance. 4

Nursing home residents with DD/MR cannot receive hypnotics for more than ten continuous days without an attempt at dose reduction. Nursing home survey guidelines discourage the use of benzodiazepines (Survey Tag F329); especially drugs with long half-lives. Conclusion Many physical, psychiatric and environmental problems can produce sleep disturbances in persons with MR/DD. Behavioral management is preferable to the use of sedative hypnotics. 5

REFERENCES DDMED 48 1. Didde R, Sigafoos J. review of the nature and treatment of sleep disorders in individuals with developmental disabilities. Res. Dev. Disabil. 2001;22(4):255-72. 2. Brylewski JE, Wiggs L. questionnaire survey of sleep and nighttime behavior in a communitybased sample of adults with intellectual disability. J Intellect Disabil. Res. 1998;42(Pt 2):154-62. 3. Lindblom N, Heiskala H, Kaski M, et al. Neurological impairments and sleep-wake behavior among the mentally retarded. J. Sleep Res. 2001;10(4):309-18. 4. Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry/V, Baltimore: Williams & Wilkins, 1989. 5. Barron J, Sandman C. Paradoxical excitement to sedative-hypnotics in mentally retarded clients. merican Journal on Mental Deficiency 1985;90(2):124-129. 6. Ryan R, Sunada K. Medical evaluation of persons with mental retardation referred for psychiatric assessment. General Hospital Psychiatry 1997;19:274-280. 7. Kastner T, Walsh KK, Fraser M. Undiagnosed medical conditions and medication side effects presenting as behavioral/psychiatric problems in people with mental retardation. Mental Health spects of Developmental Disabilities, July/ugust/September 2001;4(3):101-107. 8. Tasman, Kay J, Lieberman J (Eds.)., (2003). Psychiatry therapeutics (2 nd Edition). London: Wiley. 9. Stanish HI, Draheim CC. Walking habits of adults with mental retardation. Ment. Retard. 2005;43(6):421-427. 10. Mann J, Zhou H, McDermott S, Poston MB. Healthy behavior change of adults with mental retardation: attendance in a health promotion program. m J Ment Retard. 2006;111(1):62-73. 11. Special Issue. Expert Consensus Guidelines Series: Treatment of psychiatric and behavioral problems in mental retardation. merican Journal on Mental Retardation 2000;105(3):165-188. 12. Reiss S, man MG. The international consensus process on psychopharmacology and intellectual disability. Journal of Intellectual Disability Research 1997; 41(6):448-455. 13. Santosh PJ, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. The Lancet 1999;354:231-240. 14. Mann J, Zhou H, McDermott S, Poston MB. Healthy behavioral change of adults with mental retardation: attendance n a health promotion program. m J Ment. Retard. 2006;111(1):62-73. 15. Stanish HI, Draheim CC. Walking habits of adults with mental retardation. Ment. Retard. 2005;43(6):421-427. 6